- Home
- PULM vs TENX Comparison
PULM vs TENX Comparison
Compare PULM & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- TENX
- Stock Information
- Founded
- PULM 2003
- TENX 1967
- Country
- PULM United States
- TENX United States
- Employees
- PULM N/A
- TENX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- TENX Health Care
- Exchange
- PULM Nasdaq
- TENX Nasdaq
- Market Cap
- PULM 21.0M
- TENX 21.7M
- IPO Year
- PULM N/A
- TENX N/A
- Fundamental
- Price
- PULM $8.92
- TENX $6.75
- Analyst Decision
- PULM
- TENX Strong Buy
- Analyst Count
- PULM 0
- TENX 4
- Target Price
- PULM N/A
- TENX $20.67
- AVG Volume (30 Days)
- PULM 36.8K
- TENX 53.9K
- Earning Date
- PULM 03-27-2025
- TENX 03-27-2025
- Dividend Yield
- PULM N/A
- TENX N/A
- EPS Growth
- PULM N/A
- TENX N/A
- EPS
- PULM N/A
- TENX N/A
- Revenue
- PULM $10,005,000.00
- TENX N/A
- Revenue This Year
- PULM N/A
- TENX N/A
- Revenue Next Year
- PULM $1.00
- TENX N/A
- P/E Ratio
- PULM N/A
- TENX N/A
- Revenue Growth
- PULM 47.05
- TENX N/A
- 52 Week Low
- PULM $1.55
- TENX $2.77
- 52 Week High
- PULM $10.40
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- PULM 62.72
- TENX 51.52
- Support Level
- PULM $8.80
- TENX $6.10
- Resistance Level
- PULM $10.40
- TENX $7.69
- Average True Range (ATR)
- PULM 0.59
- TENX 0.53
- MACD
- PULM 0.15
- TENX -0.07
- Stochastic Oscillator
- PULM 56.21
- TENX 44.12
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.